Sagimet Biosciences Appoints New Directors, Adjusts Executive Pay
Ticker: SGMT · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1400118
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Sagimet adds 2 directors, revises exec pay packages.
AI Summary
Sagimet Biosciences Inc. announced on July 30, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David R. Walt and Ms. Jennifer L. D. Good, to its Board of Directors. Additionally, the company entered into new employment agreements with certain executive officers, including its Chief Executive Officer, Chief Medical Officer, and Chief Financial Officer, detailing their compensation and severance packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may affect future strategy and performance.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- Dr. David R. Walt (person) — Newly Elected Director
- Ms. Jennifer L. D. Good (person) — Newly Elected Director
- July 30, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to Sagimet Biosciences Inc.'s Board?
Dr. David R. Walt and Ms. Jennifer L. D. Good were elected as new directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated July 30, 2024.
What is the principal executive office address for Sagimet Biosciences Inc.?
The principal executive office is located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the telephone number for Sagimet Biosciences Inc.?
The telephone number is (650) 561-8600.
What other items are covered in this 8-K filing besides director changes?
This filing also covers the election of directors and compensatory arrangements of certain officers.
Filing Stats: 1,247 words · 5 min read · ~4 pages · Grade level 10.1 · Accepted 2024-08-01 08:05:10
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
- $300,000 — option with a grant date fair value of $300,000 under the Company's 2023 Stock Option a
Filing Documents
- tm2420572d1_8k.htm (8-K) — 30KB
- 0001104659-24-084645.txt ( ) — 203KB
- sgmt-20240730.xsd (EX-101.SCH) — 3KB
- sgmt-20240730_lab.xml (EX-101.LAB) — 33KB
- sgmt-20240730_pre.xml (EX-101.PRE) — 22KB
- tm2420572d1_8k_htm.xml (XML) — 4KB
02 Departure of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 30, 2024, the board of directors (the "Board") of Sagimet Biosciences Inc. (the "Company") approved the expansion of the Board from seven directors to nine directors and the appointment of each of Jennifer Jarrett and Dr. Anne Phillips to serve as directors of the Board, in each case, effective as of August 1, 2024 (the "Effective Date"). Each of Ms. Jarrett and Dr. Phillips will serve as a Class III director with a term expiring at the Company's 2025 Annual Meeting of Stockholders or until her successor is duly elected and qualified or until her earlier resignation, death or removal. As of the Effective Date, Ms. Jarrett will serve as a member of the Audit Committee of the Board and Dr. Phillips will serve as a member of the Nominating and Corporate Governance Committee of the Board. Ms. Jarrett, 53, has served as Chief Operating Officer of Arcus Biosciences, Inc. ("Arcus"), a clinical-stage, global biopharmaceutical company, since October 2020 and previously served on the board of directors of Arcus from January 2019 until January 2024. Prior to joining Arcus as Chief Operating Officer, Ms. Jarrett served as Vice President, Corporate Development and Capital Markets at Uber, Inc. (NYSE: UBER), a technology company providing a platform for mobility, delivery and freight services, from January 2019 to September 2020 and prior to that, served as Arcus' Chief Operating and Financial Officer from March 2017 to January 2019. From April 2016 to October 2016, Ms. Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. Prior to that, Ms. Jarrett spent 20 years in investment banking, most recently as Managing Director at Citigroup from July 2010 to March 2016, where she was responsible for managing their west coast life sciences investment bank